AR016134A1 - Compuestos derivados de propil-amida o butil-indanilo, composicion farmaceutica que los contiene y su uso para la fabricacion de un medicamento con metalo-proteinasas inhibidoras de la agrecanasa y matriz extracelular eficaz en el tratamiento de la artritis - Google Patents
Compuestos derivados de propil-amida o butil-indanilo, composicion farmaceutica que los contiene y su uso para la fabricacion de un medicamento con metalo-proteinasas inhibidoras de la agrecanasa y matriz extracelular eficaz en el tratamiento de la artritisInfo
- Publication number
- AR016134A1 AR016134A1 ARP980104071A ARP980104071A AR016134A1 AR 016134 A1 AR016134 A1 AR 016134A1 AR P980104071 A ARP980104071 A AR P980104071A AR P980104071 A ARP980104071 A AR P980104071A AR 016134 A1 AR016134 A1 AR 016134A1
- Authority
- AR
- Argentina
- Prior art keywords
- nra
- absent
- nrac
- alkyl
- ora
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 title 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 210000002744 extracellular matrix Anatomy 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229910003813 NRa Inorganic materials 0.000 abstract 10
- 229910052760 oxygen Inorganic materials 0.000 abstract 7
- -1 butyl-indanyl Chemical group 0.000 abstract 5
- 229910052717 sulfur Inorganic materials 0.000 abstract 5
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 101150073096 NRAS gene Proteins 0.000 abstract 2
- 125000002837 carbocyclic group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 101100440695 Dictyostelium discoideum corB gene Proteins 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000004419 alkynylene group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se relaciona con un compuesto derivado de propil-amida o butil-indanilo de formula (I) o su sal aceptable para el uso farmacéutico o esteroisomero,caracterizado porque R1 se selecciona entre: -C02H, -C(O)NHOH, -C(O)NHOR7, -SH, -CH2CO2R7, -COR7, -N(OH)COR7. -SN2H2R7, -SONHR7, -CH2CO2H, -PO(OH)2 -PO(OH)NHR7CH2SH, -C(O)NHOR7, -CO2R7, y derivados de prodrogas comunes; R2 se selecciona de la formula: U-X-Y-Z-Ua-Xa-Ya-Za donde: U está ausente o se selecciona entre:O,NRa, C(O),C(O)O,OC(O),C(O)NRa,NRaC(O),OC(O)O,OC(O)NRa,NRaC(O),NRaC(O)NRa, S(O)p, S(O)pNRa(O)p,NraS(O)p y NRaSO2NRa, X está ausente o se selecciona entre H, C1-10alquileno, C2-10 alquenileno, C2-10 alquinileno; Y está ausente o se selecciona entre H, O, NRa, S(O)p, C(O); Z está ausenteo se selecciona entre H, unresiduo carbocíclico C3-13 sustituido con O - 5 Rb y un sistema heterocíclico de 5- 14 miembros que contienen entre 1 -4 heteroátomos seleccionados del grupoformado por N, O y S sustituido con O -5 Rb, Ua está ausente o seselecciona entre: H, O NRa, C(O), C(O) O, OC(O), C(O) NRa, NRaC(O), OC(O)O, OC(O)NRa. NRaC(O)O,,NRaC(O)NRa,S(O)p,S(O)pNRa,NRaS(O)p y NRaSO2NRa;Xa está ausente o se selecciona entre H, C1-10alquileno, C2-10alquenileno, C2-10alquinileno; Ya está ausente ose selecciona entre H, O, NRa, S(O)p, y C(O); Za está ausente o se selecciona entre H, un residuo carbocíclico C3-13 sustituido con O-5Rc y un sistemaheterocíclico de 5-14 miembros que contiene entre 1-4 heteroátomos selecionados del grupo formado por N, O, y S sustituido con O -5 Rc, Ra en cada caso seselecciona independientemente entre H, C1-4 alquilo, fenilo o bencilo; Ra en cada caso se selecciona independientemente entre H, C1-4 alquilo, fenilo obencilo; como alternativa Ra y Ra juntocon el nitrogeno al cual están unidas forman un anillo de 5 o 6 miembros que contiene entre 0-1 heteroátomosadicionales seleccionados del grupo formado por N, O y S; Rb, en cada caso se selecciona independientemente entre C1-6 alquilo, ORa, Cl, F, Br, I, =O, CN, NO2,NRaRa, C(O)Ra, C(O)ORa, C(O)NRaRa, S(O)2NRaRa, S(O)pRa, CF3, y CF2CF3; Rc, en cada caso se selecciona independientemente entre C1-6 alquilo, ORa, Cl, Br, I
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5594497P | 1997-08-18 | 1997-08-18 | |
| US6833597P | 1997-12-19 | 1997-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR016134A1 true AR016134A1 (es) | 2001-06-20 |
Family
ID=26734798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980104071A AR016134A1 (es) | 1997-08-18 | 1998-08-18 | Compuestos derivados de propil-amida o butil-indanilo, composicion farmaceutica que los contiene y su uso para la fabricacion de un medicamento con metalo-proteinasas inhibidoras de la agrecanasa y matriz extracelular eficaz en el tratamiento de la artritis |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6576664B1 (es) |
| EP (1) | EP1005448A2 (es) |
| KR (1) | KR20010023001A (es) |
| CN (1) | CN1268117A (es) |
| AR (1) | AR016134A1 (es) |
| AU (1) | AU9021498A (es) |
| BR (1) | BR9815596A (es) |
| CA (1) | CA2301038A1 (es) |
| EE (1) | EE200000093A (es) |
| HR (1) | HRP980443A2 (es) |
| IL (1) | IL133952A0 (es) |
| NO (1) | NO20000784L (es) |
| PL (1) | PL339006A1 (es) |
| SK (1) | SK1602000A3 (es) |
| WO (1) | WO1999009000A2 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6747027B1 (en) | 1996-07-22 | 2004-06-08 | Pharmacia Corporation | Thiol sulfonamide metalloprotease inhibitors |
| US6696449B2 (en) | 1997-03-04 | 2004-02-24 | Pharmacia Corporation | Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors |
| US7115632B1 (en) | 1999-05-12 | 2006-10-03 | G. D. Searle & Co. | Sulfonyl aryl or heteroaryl hydroxamic acid compounds |
| US6794511B2 (en) | 1997-03-04 | 2004-09-21 | G. D. Searle | Sulfonyl aryl or heteroaryl hydroxamic acid compounds |
| US6750228B1 (en) | 1997-11-14 | 2004-06-15 | Pharmacia Corporation | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
| US20010039287A1 (en) | 1997-11-14 | 2001-11-08 | Thomas E Barta | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
| BR9814643A (pt) | 1997-11-14 | 2000-10-03 | Searle & Co | Inibidor de metaloprotease de ácido sulfona hidroxâmico aromático |
| US6800646B1 (en) | 1999-02-08 | 2004-10-05 | Pharmacia Corporation | Sulfamato hydroxamic acid metalloprotease inhibitor |
| AU4181000A (en) * | 1999-04-02 | 2000-10-23 | Du Pont Pharmaceuticals Company | Novel lactam inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase |
| US6649377B1 (en) | 1999-05-10 | 2003-11-18 | Syntex (U.S.A.) Llc | Human aggrecanase and nucleic acid compositions encoding the same |
| US6656448B1 (en) * | 2000-02-15 | 2003-12-02 | Bristol-Myers Squibb Pharma Company | Matrix metalloproteinase inhibitors |
| US6683093B2 (en) | 2000-05-12 | 2004-01-27 | Pharmacia Corporation | Aromatic sulfone hydroxamic acids and their use as protease inhibitors |
| CZ20032913A3 (cs) | 2001-05-11 | 2004-05-12 | Pharmaciaácorporation | Aromatické sulfonhydroxamáty a jejich použití jako inhibitorů proteázy |
| US6683078B2 (en) | 2001-07-19 | 2004-01-27 | Pharmacia Corporation | Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
| EP1501827A2 (en) | 2002-04-25 | 2005-02-02 | Pharmacia Corporation | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acid and their use as protease inhibitors |
| EP1583836A4 (en) * | 2002-12-11 | 2006-12-27 | Univ Massachusetts | METHOD OF INTRODUCING siRNA IN ADIPOCYTES |
| ATE464286T1 (de) * | 2003-12-15 | 2010-04-15 | Japan Tobacco Inc | Cyclopropanderivate und ihre pharmazeutische verwendung |
| US20050287121A1 (en) * | 2004-05-12 | 2005-12-29 | Merchiers Pascal G | Methods, compositions and compound assays for inhibiting amyloid-beta protein production |
| CN101426499A (zh) | 2006-02-22 | 2009-05-06 | 弗特克斯药品有限公司 | 毒蕈碱受体调节剂 |
| NZ580802A (en) * | 2007-05-10 | 2012-09-28 | Albany Molecular Res Inc | Aryloxy-and heteroaryloxy-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| JP5420761B2 (ja) * | 2009-05-28 | 2014-02-19 | ノバルティス アーゲー | ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体 |
| WO2013070471A1 (en) | 2011-11-11 | 2013-05-16 | Lantheus Medical Imaging, Inc. | Evaluation of presence of and vulnerability to atrial fibrillation and other indications using matrix metalloproteinase-based imaging |
| WO2016105118A2 (ko) | 2014-12-24 | 2016-06-30 | 주식회사 엘지생명과학 | Gpr120 효능제로서의 바이아릴 유도체 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8827308D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| GB9102635D0 (en) | 1991-02-07 | 1991-03-27 | British Bio Technology | Compounds |
| WO1992021360A1 (en) | 1991-05-28 | 1992-12-10 | Merck & Co., Inc. | Substituted n-carboxyalkylpeptidyl derivatives as antidegenerative active agents |
| US5413999A (en) * | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| US5318964A (en) | 1992-06-11 | 1994-06-07 | Hoffmann-La Roche Inc. | Hydroxamic derivatives and pharmaceutical compositions |
| GB2268935B (en) | 1992-06-24 | 1996-10-23 | Nat Heart & Lung Inst | Diagnosis of rejection of transplanted organs |
| GB9215665D0 (en) * | 1992-07-23 | 1992-09-09 | British Bio Technology | Compounds |
| GB9307956D0 (en) | 1993-04-17 | 1993-06-02 | Walls Alan J | Hydroxamic acid derivatives |
| GB9320660D0 (en) | 1993-10-07 | 1993-11-24 | British Bio Technology | Inhibition of cytokine production |
| US5508404A (en) * | 1995-03-15 | 1996-04-16 | Merck & Co., Inc. | Reductive amination process |
| US6008243A (en) * | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
-
1998
- 1998-08-14 US US09/134,484 patent/US6576664B1/en not_active Expired - Lifetime
- 1998-08-14 HR HR60/068,335A patent/HRP980443A2/hr not_active Application Discontinuation
- 1998-08-18 WO PCT/US1998/017048 patent/WO1999009000A2/en not_active Ceased
- 1998-08-18 EP EP98942083A patent/EP1005448A2/en not_active Withdrawn
- 1998-08-18 AR ARP980104071A patent/AR016134A1/es not_active Application Discontinuation
- 1998-08-18 IL IL13395298A patent/IL133952A0/xx unknown
- 1998-08-18 AU AU90214/98A patent/AU9021498A/en not_active Abandoned
- 1998-08-18 SK SK160-2000A patent/SK1602000A3/sk unknown
- 1998-08-18 BR BR9815596-2A patent/BR9815596A/pt not_active IP Right Cessation
- 1998-08-18 KR KR1020007001609A patent/KR20010023001A/ko not_active Withdrawn
- 1998-08-18 CA CA002301038A patent/CA2301038A1/en not_active Abandoned
- 1998-08-18 PL PL98339006A patent/PL339006A1/xx unknown
- 1998-08-18 CN CN98807928A patent/CN1268117A/zh active Pending
- 1998-08-18 EE EEP200000093A patent/EE200000093A/xx unknown
-
2000
- 2000-02-17 NO NO20000784A patent/NO20000784L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20000784L (no) | 2000-04-07 |
| KR20010023001A (ko) | 2001-03-26 |
| HRP980443A2 (en) | 1999-10-31 |
| NO20000784D0 (no) | 2000-02-17 |
| PL339006A1 (en) | 2000-12-04 |
| WO1999009000A3 (en) | 1999-09-10 |
| EP1005448A2 (en) | 2000-06-07 |
| WO1999009000A2 (en) | 1999-02-25 |
| US6576664B1 (en) | 2003-06-10 |
| BR9815596A (pt) | 2001-01-02 |
| AU9021498A (en) | 1999-03-08 |
| EE200000093A (et) | 2000-12-15 |
| CA2301038A1 (en) | 1999-02-25 |
| CN1268117A (zh) | 2000-09-27 |
| SK1602000A3 (en) | 2000-09-12 |
| IL133952A0 (en) | 2001-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR016134A1 (es) | Compuestos derivados de propil-amida o butil-indanilo, composicion farmaceutica que los contiene y su uso para la fabricacion de un medicamento con metalo-proteinasas inhibidoras de la agrecanasa y matriz extracelular eficaz en el tratamiento de la artritis | |
| PT96890A (pt) | Processo para a preparacao de novos derivados com estrutura naftalenica e de composicoes farmaceuticas que os contem | |
| AR017164A1 (es) | Derivados de la benzamidina, un procedimiento para prepararlos, el empleo de los mismos para preparar un medicamento, los medicamentos y laspreparaciones farmaceuticas que contienen estos derivados de la benzamidina, y un procedimiento para obtener estas preparaciones farmaceuticas. | |
| PE20212302A1 (es) | Inhibidores de apol1 y sus metodos de uso | |
| AR029766A1 (es) | Compuesto inhibidor de quinasa y uso del mismo para preparar una composicion farmaceutica | |
| AR247721A1 (es) | Un procedimiento para la preparacion de compuestos de fenetanolamina y sus sales y solvatos farmaceuticamente aceptables | |
| DE69604714D1 (de) | Stilbenderivate und diese enthaltende pharmazeutische Zusammensetzungen | |
| AR048213A1 (es) | 1-(4-mono-y di-halometilsulfonilfenil)-2-acilamino-fluorpropanoles analogos al florfenicol | |
| AR028914A1 (es) | 2-guanidino-4-aril-quinazolinas como inhibidores de nhe-3 | |
| KR910006277A (ko) | N-치환된-4-피리미딘아민 및 피리미딘디아민, 이의 제조방법 및 약제로서의 이의 용도 | |
| AR245447A1 (es) | Procedimiento para preparar derivados de 2,4-diamino-5-(biciclo-sustituido)metilpirimidinas. | |
| AR035479A1 (es) | Derivados de eteres biarilicos y sus sales, composiciones farmaceuticas que los comprenden y procedimientos para el tratamiento de trastornos o afecciones | |
| AR041271A1 (es) | Quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa | |
| DK0391799T3 (da) | Sulfonamider afledt af benzocykliske eller benzoheterocykliske syrer, fremstilling deraf samt anvendelse deraf til terapi | |
| AR008234A1 (es) | Derivados de benzamidas, procedimiento para su preparacion, composiciones farmaceuticas y su uso para la preparacion de un medicamento | |
| AR016644A1 (es) | Compuestos de 2-aminopiridinas con sustituyentes alcoxi ramificados, composicion farmaceutica y uso para la manufactura de medicamentos | |
| AR031101A1 (es) | Compuestos de n-(2-hidroxi-3-aminosulfonil-fenil)-n'-fenil guanidina, composiciones farmaceuticasque los comprenden, y uso de dichos compuestos en la manufactura de medicamentos para tratar enfermedades que cursan con mediacion de quimioquinas. | |
| ES2135695T3 (es) | Derivados de aminoacidos y su uso como inhibidores de la fosfolipasa a2. | |
| BR9814495A (pt) | Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo | |
| ES2183492T3 (es) | Nuevos derivados de nitrono,su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| PT861837E (pt) | Novos compostos de 2-amino-indano processo para a sua preparacao e as composicoes farmaceuticas que os contem | |
| AR005549A1 (es) | Derivados de la 1-pirazol-3-iletil-4-indol-3-ilpiperidina, un procedimiento para prepararlos, medicamentos y preparaciones farmaceuticas que los contienen,un procedimiento para preparar las preparaciones farmaceuticas y empleo de los mismos para la preparacion de medicamentos. | |
| AR034692A1 (es) | Inhibidores de la integrina alfavbeta3, un procedimiento para su preparacion, los medicamentos a base de estos compuestos, las composiciones farmaceuticas que los contienen y el uso de los mismos para preparar un medicamento destinado a combatir enfermedades que se basan en la expresion y funcion pa | |
| PT937043E (pt) | Novos derivados tetra-hidropiridinicos substituidos processo para a sua preparacao e as composicoes farmaceuticas que os contem | |
| AR019264A1 (es) | Derivados de bifenilo, un procedimiento para su preparacion, el empleo de los mismos para preparar un medicamento, los medicamentos a base de estoscompuestos, las composiciones farmaceuticas que los contienen y un procedimiento para preparar estas composiciones farmaceuticas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |